glp-1 tripeptide A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss but the FDA has not evaluated the medications for safety Compounded GLP-1 - Semaglutide &

compared with maternal blood, especially in NAC-treated moderate IPTB cases

Oral Treatments: Emerging Systemic Options for Melasma Tranexamic Acid (Oral Use) One of the most promising oral treatments

In the PIONEER trial program, oral semaglutide 14 mg produced HbA1c reductions of approximately 1.0-1.4% and weight loss of 3-5 kg at 26-52 weeks, meaningful but below the efficacy achievable with injectable semaglutide 2.4 mg or tirzepatide

Less common but more serious adverse reactions include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when used in combination with insulin or sulphonylureas)